Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Genprex ( (GNPX) ) has provided an update.
On November 18, 2025, Genprex announced that it has been granted a U.S. patent for its lead drug candidate, Reqorsa® Gene Therapy, in combination with PD-L1 antibodies, securing exclusivity through 2037. This patent supports the Acclaim-3 clinical trial, which is evaluating the combination as a maintenance therapy for extensive stage small cell lung cancer. The trial, supported by FDA Fast Track and Orphan Drug Designations, aims to determine the progression-free survival rate and is expected to complete interim analysis in the first half of 2026.
More about Genprex
Genprex, Inc. operates in the biotechnology industry, focusing on developing gene therapies for cancer and diabetes. Its primary product is Reqorsa® Gene Therapy, which is being tested in combination with PD-L1 antibodies for cancer treatment.
Average Trading Volume: 760,843
Technical Sentiment Signal: Sell
Current Market Cap: $8.62M
Learn more about GNPX stock on TipRanks’ Stock Analysis page.